Chief, Early-Phase Drug Development|@SarahCannonDocs
#Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
2/15 📊 The numbers are staggering:
1/n The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development #TissueAgnostic #PrecisionMedicine
There is an urgent need to reinvigorate clinical trials through drug discovery, interpreting imaging, streamlining electronic health records, and improving workflow, over time advancing public health. AI can aid in many of these aspects in all stages of drug development. 
First 2022 saw publication of Hallmarks of Cancer: New Dimensions @CD_AACR @AACR @ElizSMcKenna 
Lurbinectedin has antitumor activity against homologous recombination repair-deficient (HRD) cell lines. The mechanism involves irreversible stalling of elongating RNA polymerase II (Pol II) on DNA template and its specific degradation by the ubiquitin/proteasome machinery 2/4
2/6 Prognosis for patients with metastatic bladder carcinoma (mBC) remains limited and in need of novel therapies @OncoAlert @MCR_AACR @oalhalabimd . #bcsm bit.ly/3d25A1U
1. Pembrolizumab led to significantly longer progression-free survival vs chemotherapy as first-line therapy for MSI-H–dMMR metastatic colorectal cancer 👉Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer @NEJM @agrothey nejm.org/doi/full/10.10…
# 2The Master Observational Trial (MOT)-->Patients are broadly accepted into the trial along with diagnosis + staging info. Biomarker testing results (both positive and negative) are collected & classified using methods shown in Figures 1A and 1B. 
RET Fusions are bonafide #lung cancer drivers #LSCM 